The estimated Net Worth of John A Lambert is at least $1.08 Milione dollars as of 2 July 2009. John Lambert owns over 34,746 units of Novavax stock worth over $983,200 and over the last 18 years John sold NVAX stock worth over $97,984.
John has made over 1 trades of the Novavax stock since 2009, according to the Form 4 filled with the SEC. Most recently John sold 34,746 units of NVAX stock worth $97,984 on 2 July 2009.
The largest trade John's ever made was selling 34,746 units of Novavax stock on 2 July 2009 worth over $97,984. On average, John trades about 4,964 units every 0 days since 2007. As of 2 July 2009 John still owns at least 80,000 units of Novavax stock.
You can see the complete history of John Lambert stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O NOVAVAX, INC., 9920 BELWARD CAMPUS DRIVE, ROCKVILLE, MD, 20850.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi e Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: